Procept BioRobotics [PRCT] vs Boston Scientific [BSX] Detailed Stock Comparison
Procept BioRobotics
NASDAQ
Loading...
Boston Scientific
NYSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Procept BioRobotics wins in 6 metrics, Boston Scientific wins in 12 metrics, with 0 ties. Boston Scientific appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Procept BioRobotics | Boston Scientific | Better |
|---|---|---|---|
| P/E Ratio (TTM) | -19.85 | 57.40 | Procept BioRobotics |
| Price-to-Book Ratio | 5.14 | 6.33 | Procept BioRobotics |
| Debt-to-Equity Ratio | 20.57 | 53.09 | Procept BioRobotics |
| PEG Ratio | 0.66 | 0.39 | Boston Scientific |
| EV/EBITDA | -20.51 | 33.24 | Procept BioRobotics |
| Profit Margin (TTM) | -30.60% | 13.55% | Boston Scientific |
| Operating Margin (TTM) | -28.02% | 18.63% | Boston Scientific |
| EBITDA Margin (TTM) | N/A | 18.63% | N/A |
| Return on Equity | -26.40% | 11.55% | Boston Scientific |
| Return on Assets (TTM) | -12.93% | 5.39% | Boston Scientific |
| Free Cash Flow (TTM) | $-103.62M | $2.37B | Boston Scientific |
| Dividend Yield | 0.64% | N/A | N/A |
| 1-Year Return | -52.11% | 13.82% | Boston Scientific |
| Price-to-Sales Ratio (TTM) | 7.42 | 7.72 | Procept BioRobotics |
| Enterprise Value | $1.76B | $156.39B | Boston Scientific |
| EV/Revenue Ratio | 6.41 | 8.46 | Procept BioRobotics |
| Gross Profit Margin (TTM) | 65.35% | 67.65% | Boston Scientific |
| Revenue per Share (TTM) | $5 | $13 | Boston Scientific |
| Earnings per Share (Diluted) | $-1.50 | $1.67 | Boston Scientific |
| Beta (Stock Volatility) | 1.03 | 0.66 | Boston Scientific |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Procept BioRobotics vs Boston Scientific Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Procept BioRobotics | 0.20% | -6.00% | -12.05% | -40.19% | -39.73% | -58.15% |
| Boston Scientific | 0.39% | -1.96% | -9.79% | -7.15% | -3.83% | 7.65% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Procept BioRobotics | -52.11% | -13.09% | -13.00% | -13.00% | -13.00% | -13.00% |
| Boston Scientific | 13.82% | 142.00% | 133.88% | 470.02% | 1,469.66% | 307.71% |
News Based Sentiment: Procept BioRobotics vs Boston Scientific
Procept BioRobotics
News based Sentiment: MIXED
September presented a mixed bag for Procept BioRobotics, with strong Q2 earnings and positive analyst ratings countered by stock volatility, insider selling, and downward price target revisions. The conflicting signals create a complex investment picture, making it a significant month for the company's trajectory.
Boston Scientific
News based Sentiment: POSITIVE
October brought a wave of positive signals for Boston Scientific, including increased institutional investment, raised price targets from multiple firms, and a promising long-range plan. While insider selling remains a point to watch, the overall narrative is one of strong growth potential and investor confidence.
Performance & Financial Health Analysis: Procept BioRobotics vs Boston Scientific
| Metric | PRCT | BSX |
|---|---|---|
| Market Information | ||
| Market Cap | $1.99B | $142.83B |
| Market Cap Category | Small cap | Large cap |
| 10 Day Avg. Volume | 902,800 | 11,631,001 |
| 90 Day Avg. Volume | 951,347 | 9,170,397 |
| Last Close | $34.80 | $96.22 |
| 52 Week Range | $34.01 - $103.81 | $80.64 - $109.50 |
| % from 52W High | -66.48% | -12.13% |
| All-Time High | $103.81 (Nov 11, 2024) | $109.50 (Sep 09, 2025) |
| % from All-Time High | -66.48% | -12.13% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.48% | 0.23% |
| Quarterly Earnings Growth | 0.48% | 1.46% |
| Financial Health | ||
| Profit Margin (TTM) | -0.31% | 0.14% |
| Operating Margin (TTM) | -0.28% | 0.19% |
| Return on Equity (TTM) | -0.26% | 0.12% |
| Debt to Equity (MRQ) | 20.57 | 53.09 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $6.94 | $15.14 |
| Cash per Share (MRQ) | $5.44 | $0.36 |
| Operating Cash Flow (TTM) | $-83,214,000 | $4.28B |
| Levered Free Cash Flow (TTM) | $-59,140,124 | $2.94B |
| Dividends | ||
| Last 12-Month Dividend Yield | 0.64% | N/A |
| Last 12-Month Dividend | $0.38 | N/A |
Valuation & Enterprise Metrics Analysis: Procept BioRobotics vs Boston Scientific
| Metric | PRCT | BSX |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | -19.85 | 57.40 |
| Forward P/E | -26.83 | 34.35 |
| PEG Ratio | 0.66 | 0.39 |
| Price to Sales (TTM) | 7.42 | 7.72 |
| Price to Book (MRQ) | 5.14 | 6.33 |
| Market Capitalization | ||
| Market Capitalization | $1.99B | $142.83B |
| Enterprise Value | $1.76B | $156.39B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 6.41 | 8.46 |
| Enterprise to EBITDA | -20.51 | 33.24 |
| Risk & Other Metrics | ||
| Beta | 1.03 | 0.66 |
| Book Value per Share (MRQ) | $6.94 | $15.14 |
Financial Statements Comparison: Procept BioRobotics vs Boston Scientific
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | PRCT | BSX |
|---|---|---|
| Revenue/Sales | $69.16M | $4.66B |
| Cost of Goods Sold | $25.00M | $1.45B |
| Gross Profit | $44.16M | $3.21B |
| Research & Development | $16.40M | $443.00M |
| Operating Income (EBIT) | $-27.44M | $937.00M |
| EBITDA | $-22.39M | $1.23B |
| Pre-Tax Income | $-24.74M | $805.00M |
| Income Tax | N/A | $133.00M |
| Net Income (Profit) | $-24.74M | $672.00M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | PRCT | BSX |
|---|---|---|
| Cash & Equivalents | $316.21M | $725.00M |
| Total Current Assets | $465.79M | $7.34B |
| Total Current Liabilities | $52.06M | $5.06B |
| Long-Term Debt | $77.83M | $10.93B |
| Total Shareholders Equity | $389.16M | $22.45B |
| Retained Earnings | $-570.72M | $3.35B |
| Property, Plant & Equipment | $21.26M | $448.00M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | PRCT | BSX |
|---|---|---|
| Operating Cash Flow | $-11.65M | $513.00M |
| Capital Expenditures | $-1.84M | $-187.00M |
| Free Cash Flow | $-18.82M | $277.00M |
| Debt Repayment | N/A | $-1.31B |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | PRCT | BSX |
|---|---|---|
| Shares Short | 8.15M | 19.02M |
| Short Ratio | 8.52 | 2.76 |
| Short % of Float | 0.17% | 0.01% |
| Average Daily Volume (10 Day) | 902,800 | 11,631,001 |
| Average Daily Volume (90 Day) | 951,347 | 9,170,397 |
| Shares Outstanding | 54.72M | 1.47B |
| Float Shares | 53.56M | 1.48B |
| % Held by Insiders | 0.05% | 0.00% |
| % Held by Institutions | 0.98% | 0.94% |
Dividend Analysis & Yield Comparison: Procept BioRobotics vs Boston Scientific
| Metric | PRCT | BSX |
|---|---|---|
| Last 12-Month Dividend | $0.38 | N/A |
| Last 12-Month Dividend Yield | 0.64% | N/A |
| 3-Year Avg Annual Dividend | $0.53 | N/A |
| 3-Year Avg Dividend Yield | 0.12% | N/A |
| 3-Year Total Dividends | $1.59 | N/A |
| Ex-Dividend Date | Mar 31, 2025 | N/A |